Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.

Clicks: 96
ID: 278385
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #138 of 149 articles by views in JAMA

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 149 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.To determine whether vitamin C improves outcomes for patients with COVID-19.Two prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support in intensive care units (90 sites) and patients who were not critically ill (40 sites) between July 23, 2020, and July 15, 2022, on 4 continents.Patients were randomized to receive vitamin C administered intravenously or control (placebo or no vitamin C) every 6 hours for 96 hours (maximum of 16 doses).The primary outcome was a composite of organ support-free days defined as days alive and free of respiratory and cardiovascular organ support in the intensive care unit up to day 21 and survival to hospital discharge. Values ranged from -1 organ support-free days for patients experiencing in-hospital death to 22 organ support-free days for those who survived without needing organ support. The primary analysis used a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented efficacy (improved survival, more organ support-free days, or both), an OR less than 1 represented harm, and an OR less than 1.2 represented futility.Enrollment was terminated after statistical triggers for harm and futility were met. The trials had primary outcome data for 1568 critically ill patients (1037 in the vitamin C group and 531 in the control group; median age, 60 years [IQR, 50-70 years]; 35.9% were female) and 1022 patients who were not critically ill (456 in the vitamin C group and 566 in the control group; median age, 62 years [IQR, 51-72 years]; 39.6% were female). Among critically ill patients, the median number of organ support-free days was 7 (IQR, -1 to 17 days) for the vitamin C group vs 10 (IQR, -1 to 17 days) for the control group (adjusted proportional OR, 0.88 [95% credible interval {CrI}, 0.73 to 1.06]) and the posterior probabilities were 8.6% (efficacy), 91.4% (harm), and 99.9% (futility). Among patients who were not critically ill, the median number of organ support-free days was 22 (IQR, 18 to 22 days) for the vitamin C group vs 22 (IQR, 21 to 22 days) for the control group (adjusted proportional OR, 0.80 [95% CrI, 0.60 to 1.01]) and the posterior probabilities were 2.9% (efficacy), 97.1% (harm), and greater than 99.9% (futility). Among critically ill patients, survival to hospital discharge was 61.9% (642/1037) for the vitamin C group vs 64.6% (343/531) for the control group (adjusted OR, 0.92 [95% CrI, 0.73 to 1.17]) and the posterior probability was 24.0% for efficacy. Among patients who were not critically ill, survival to hospital discharge was 85.1% (388/456) for the vitamin C group vs 86.6% (490/566) for the control group (adjusted OR, 0.86 [95% CrI, 0.61 to 1.17]) and the posterior probability was 17.8% for efficacy.In hospitalized patients with COVID-19, vitamin C had low probability of improving the primary composite outcome of organ support-free days and hospital survival.ClinicalTrials.gov Identifiers: NCT04401150 (LOVIT-COVID) and NCT02735707 (REMAP-CAP).
Reference Key
nolastname2023intravenousjama Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors , ;Adhikari, Neill K J;Hashmi, Madiha;Tirupakuzhi Vijayaraghavan, Bharath Kumar;Haniffa, Rashan;Beane, Abi;Webb, Steve A;Angus, Derek C;Gordon, Anthony C;Cook, Deborah J;Guyatt, Gordon H;Berry, Lindsay R;Lorenzi, Elizabeth;Mouncey, Paul R;Au, Carly;Pinto, Ruxandra;Ménard, Julie;Sprague, Sheila;Masse, Marie-Hélène;Huang, David T;Heyland, Daren K;Nichol, Alistair D;McArthur, Colin J;de Man, Angelique;Al-Beidh, Farah;Annane, Djillali;Anstey, Matthew;Arabi, Yaseen M;Battista, Marie-Claude;Berry, Scott;Bhimani, Zahra;Bonten, Marc J M;Bradbury, Charlotte A;Brant, Emily B;Brunkhorst, Frank M;Burrell, Aidan;Buxton, Meredith;Cecconi, Maurizio;Cheng, Allen C;Cohen, Dian;Cove, Matthew E;Day, Andrew G;Derde, Lennie P G;Detry, Michelle A;Estcourt, Lise J;Fagbodun, Elizabeth O;Fitzgerald, Mark;Goossens, Herman;Green, Cameron;Higgins, Alisa M;Hills, Thomas E;Ichihara, Nao;Jayakumar, Devachandran;Kanji, Salmaan;Khoso, Muhammad Nasir;Lawler, Patrick R;Lewis, Roger J;Litton, Edward;Marshall, John C;McAuley, Daniel F;McGlothlin, Anna;McGuinness, Shay P;McQuilten, Zoe K;McVerry, Bryan J;Murthy, Srinivas;Parke, Rachael L;Parker, Jane C;Reyes, Luis Felipe;Rowan, Kathryn M;Saito, Hiroki;Salahuddin, Nawal;Santos, Marlene S;Saunders, Christina T;Seymour, Christopher W;Shankar-Hari, Manu;Tolppa, Timo;Trapani, Tony;Turgeon, Alexis F;Turner, Anne M;Udy, Andrew A;van de Veerdonk, Frank L;Zarychanski, Ryan;Lamontagne, François;
Journal JAMA
Year 2023
DOI
10.1001/jama.2023.21407
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.